{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:25:30Z","timestamp":1777987530719,"version":"3.51.4"},"reference-count":40,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:p>Recent phase 3 trials have generated clinically actionable data that help define neoadjuvant therapy for localized pancreatic ductal adenocarcinoma, while exposing the limitations of anatomic patient selection. Emerging evidence signals that the field is poised to transition toward biology\u2010driven, response\u2010adaptive frameworks.<\/jats:p>","DOI":"10.1002\/cncr.70431","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:31:27Z","timestamp":1777714287000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Top advances of the year: Neoadjuvant therapy in pancreatic cancer"],"prefix":"10.1002","volume":"132","author":[{"given":"Jorge I.","family":"Portuondo","sequence":"first","affiliation":[{"name":"The Department of Surgical Oncology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3870-6968","authenticated-orcid":false,"given":"Matthew H. G.","family":"Katz","sequence":"additional","affiliation":[{"name":"The Department of Surgical Oncology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1011923"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1304369"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1809775"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01134"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco\u201024\u201001378"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2468\u20101253(22)00348\u2010x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2319"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000004155"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(25)01685\u2010x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2468\u20101253(18)30081\u20105"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000000378"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11605\u2010013\u20102412\u20101"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0329"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010024\u201015579\u20100"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00489"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006562"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae244"},{"key":"e_1_2_6_20_1","article-title":"NeoOPTIMIZE: phase II trial of adaptive switching of neoadjuvant FOLFIRINOX to gemcitabine\/nab\u2010paclitaxel in R\/BR\/LA pancreatic adenocarcinoma","volume":"43","author":"Lopez CD","year":"2025","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4324"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco\u201024\u201001502"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2304"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02233"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(25)00363\u20108"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000006910"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2468\u20101253(23)00405\u20103"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000006730"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.tps4204"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010023\u201011141\u20105"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34273"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1903387"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.tps4202"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.can\u201019\u20103682"},{"key":"e_1_2_6_35_1","unstructured":"Revolution Medicines.FDA breakthrough therapy designation for daraxonrasib in previously treated metastatic pancreatic cancer with KRAS G12 mutations. Published 23 June 2025."},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.tps4230"},{"key":"e_1_2_6_37_1","unstructured":"Revolution Medicines.Daraxonrasib demonstrates unprecedented overall survival benefit in pivotal phase 3 RASolute 302 clinical trial in patients with metastatic pancreatic cancer.2026.https:\/\/ir.revmed.com\/news\u2010releases\/news\u2010release\u2010details\/daraxonrasib\u2010demonstrates\u2010unprecedented\u2010overall\u2010survival\u2010benefit"},{"key":"e_1_2_6_38_1","unstructured":"Revolution Medicines Inc.Study of daraxonrasib (RMC\u20106236) in patients with resected pancreatic ductal adenocarcinoma (PDAC). ClinicalTrials.gov identifier: NCT07252232. Accessed March 29 2026.https:\/\/clinicaltrials.gov\/study\/NCT07252232"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4011"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.519"},{"issue":"11","key":"e_1_2_6_41_1","first-page":"2020","article-title":"Neoadjuvant pembrolizumab for patients with mismatch repair\u2010deficient or microsatellite instability\u2010high solid tumors","volume":"41","author":"Ludford K","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70431","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70431","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:44:44Z","timestamp":1777985084000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,1]]}},"alternative-id":["10.1002\/cncr.70431"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70431","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"2026-05-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70431"}}